Navigation Links
Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
Date:11/9/2009

BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.

The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.

"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship."

Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts."

Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation and development problems. Bend Research prides itself in offering fast, innovative solutions.

Since late 2008, Bend Research has been rapidly expanding its line-up of industrial partners. Customers that have benefitted from Bend Research's proprietary technology and unique formulation expertise include some two dozen major pharmaceutical companies, mid-size pharmas, and biotech companies around the globe.

About Bend Research Inc.

Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies. The firm develops innovative drug-delivery solutions from a solid base of fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.

The company's flexible, client-focused business model and collaborative approach to working with its customers enable long-term alliances with clients focused on value creation.

Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small-molecule drugs for serious diseases. The company's strategy is to commercialize products independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

    Contact:

    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701

    Phone: +1(541)-382-4100
    Fax: +1(541)-382-2713
    E-mail: settell@bendres.com

SOURCE Bend Research Inc.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):